| Literature DB >> 34836010 |
Fernanda Cristofori1, Fulvio Salvatore D'Abramo2, Vincenzo Rutigliano1, Vanessa Nadia Dargenio1, Stefania Castellaneta1, Domenico Piscitelli3, Davide De Benedittis4, Flavia Indrio5, Lidia Celeste Raguseo1, Michele Barone2, Ruggiero Francavilla1.
Abstract
The association between eosinophilic esophagitis and celiac disease is still controversial and its prevalence is highly variable. We aimed to investigate the prevalence of esophageal eosinophilia and eosinophilic esophagitis in a large group of children with celiac disease, prospectively followed over 11 years.Entities:
Keywords: celiac disease; eosinophilic esophagitis; eosinophilic gastrointestinal disorders; esophageal eosinophilia
Mesh:
Year: 2021 PMID: 34836010 PMCID: PMC8625488 DOI: 10.3390/nu13113755
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flow diagram of participants. CD: Celiac disease; EoE: Eosinophilic esophagitis; EsEo: Esophageal eosinophilia; ESPGHAN: European Society of Gastroenterology, Hepatology and Nutrition; GFD: gluten-free diet.
Clinical presentation, endoscopic and histological findings of children with celiac disease and esophageal eosinophilia/eosinophilic esophagitis.
| N | Sex | Age | Symptoms | Atopy | Endoscopic Finding Esophagus | HP | Eosinophil | Treatment | Duodenal |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 2 | AP; Diarrhea | Yes | Normal | Neg | 25 | Marsh 3a | |
| Normal | - | ||||||||
| Scalloping | |||||||||
| 2 | M | 5.6 | AP; Diarrhea; | Yes | Normal | Neg | 45 | Marsh 3c | |
| Mild gastritis | - | ||||||||
| Scalloping | |||||||||
| 3 | F | 3.9 | Dyspepsia | No | White exudates | Neg | 50 | Marsh 3c | |
| Normal | PPI | ||||||||
| Scalloping | |||||||||
| 4 * | M | 5 | Dysphagia | Yes | Esophageal trachealization | Neg | 25 | swallowed Fluticasone | Marsh 3c |
| Normal | |||||||||
| Scalloping | |||||||||
| 5 | M | 6.4 | Anemia | No | Longitudinal furrowing | Neg | 40 | - | Marsh 3a |
| Mild gastritis | |||||||||
| Scalloping |
AP: Abdominal Pain; FI: Food Impaction; HP: Helicobacter Pylori; HPF: High power field; IgA: Immunoglobulin A; IgE immunoglobulin E; Neg: negative; PPI: proton pump inhibitors; TTG: Tissue transglutaminase. * Patient with CD and eosinophilic esophagitis.
Auxological, nutritional, biochemical and hematological parameters of children with celiac disease vs. children with celiac disease and esophageal eosinophilia.
| CD | CD-EsEo | ||
|---|---|---|---|
| Median Age (range) | 7.1 ± 6.3 | 4.5 ± 1.7 | |
| Gender (F/M) | 184/124 | 1/4 | |
| History of atopy (%) | 10.6 | 60 | |
| Weight Centile (mean ± sd) | 64.6 ± 31 | 58.3 ± 24 | |
| Height Centile (mean ± sd) | 59.2 ± 27 | 44.5 ± 28 | |
| Iron (mean ± sd) µg/dL | 65.3 ± 34 | 44.3 ± 33.9 | |
| Ferritin (mean ± sd) ng/mL | 29.7 ± 21.7 | 32 ± 11.5 | |
| Albumin (mean ± sd) g/dL | 3.6 ± 0.5 | 3.2 ± 2.1 | |
| Serum glucose (mean ± sd) mg/dL | 85.3 ± 7.1 | 79.3 ± 6.4 | |
| Hemoglobin (mean ± sd) g/dL | 12.2 ± 0.4 | 11.7 ± 0.5 | |
| Alanine aminotrasferase (mean ± sd) UI/dL | 44 ± 13 | 39 ± 12 | |
| IgE (mean ± sd) g/dL | 122 ± 104 | 51.2 ± 26.2 | |
| Tissue trasglutaminase-IgA (mean ± sd) UI/L | 142.5 ± 166 | 54.8 ± 26 |
CD: Celiac disease; EsEo: Esophageal eosinophilia; IgE: Immunoglobulin E; NS: Not significant.
Prevalence of eosinophilic esophagitis in the population with Celiac disease, based on published trials.
| First Author, Publication Year | P ( | Study Period | Design | Outcome Indicator | Gender | Age Years | Response to GFD | Response to GFD |
|---|---|---|---|---|---|---|---|---|
| Quaglietta L.—2007 [ | 315 | 2005–2006 | Prospective | 1.9% (6 EoE/315 CD) | 2⁄4 | 5.6 (4–10) | 6/6 clinical remission | 3/3 histological remission |
| Ooi CY.—2008 [ | 221 | 2000–2007 | Retrospective | 3.2% (7 EoE/221 CD) | 3/4 | 5.4 (4.2–10) | 1/5 clinical improvement | 1/2 improvement (on GFD + PPI) |
| Leslie C.—2010 [ | 121 | 1999–2007 | Retrospective | 4% (10 EoE/250 CD) | 6/4 | 8.5 (2–14) | Not reported | 4/4persistent EoE |
| Abraham JR.—2012 [ | 206 | 2009–2011 | Retrospective | 4.4% (9 EoE/206 CD) | 4/5 | 11.3 (8–15) | Not reported | 6/98persistent EoE |
| Thompson JS.—2012 [ | 297 | 1981–2012 | Retrospective | 1.3% (4 EoE/297 CD) | 2/2 | 8 (6–13) | Not reported | Not reported |
| Stewart MJ.—2013 [ | 245 | 2004–2008 | Retrospective | 1.2% (3 EoE) | 3/0 | 13 (11–15) | Not reported | Not reported |
| Dharmaraj R.—2014 [ | 56 | 2010–2013 | Retrospective | 10,7% (6 EoE/56 CD) | 5/1 | 11.6 | 2/6 improvement | 2/6 remission (on GFD + PPI) |
| Ahmed OI.—2015 [ | 220 | 2007–2012 | Retrospective | 6.5% (4 EoE/62 CD) | 4/0 | Not reported | Not reported | Not reported |
| Hommeida S.—2017 [ | 546 | 1998–2015 | Retrospective | 1.86 (10 EoE/V 546 CD); | 7/3 | 9 (2–17) | 3/10 clinical remission (GFD) | 4/4 resolution (on GFD, +swallowed steroid/diet) |
| Ari A.—2017 [ | 612 | 2000–2014 | Retrospective | 5.3 (17 EoE/319 CD) | 11/6 | 5.8 (1–8) | Not reported | 3/14 resolution (GFD) |
| Patton T.—2019 [ | 350 | 2008–2013 | Retrospective | 6.3 (22 EoE/350 CD) | 15/7 | 10.2 (4–17) | Not reported | 4/12 resolution (GFD) |
§: Number of patients/number of available follow ups. P: Population; CD: Celiac disease; EoE Eosinophilic esophagitis; GFD: Gluten free diet; PPI: Proton pump inhibitor.